港股異動 | 榮昌生物-B(9995.HK)漲9%破頂 市值達400億港元
格隆匯12月21日丨榮昌生物-B(9995.HK)漲幅擴大至8.87%,盤中高見81.75港元創新高價,暫成交9751萬港元,總市值400億港元。據CDE官網顯示,榮昌生物的ADC產品維迪西妥單抗,擬被納入突破性治療品種,擬認定的適應症為,既往經過化療失敗後進展的HER2過表達局部晚期或轉移性尿路上皮癌。與標準治療手段相比,該藥物具備更好的親和性,旁殺效應更強。此外,小摩日前指出,榮昌生物兩款主要的研發後期候選藥物RC18和RC48具有高度差異化的臨牀效果,令公司在中國以至全球都具有強大競爭力,加上公司擁有深厚的產品線及強大的藥物研發引擎,料在全球發展戰略及經驗豐富的管理層領導下,可實現持續增長,首次給予“增持”評級,目標價90港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.